Active substance
Results for the substance mirvetuximab soravtansin
1 result
About this active substance
Mirvetuximab soravtansine is a monoclonal antibody-drug conjugate used for the treatment of certain types of epithelial ovarian cancer, particularly in patients with high expression of the folate receptor alpha (FRα). It works by delivering a cytotoxic agent to cancer cells expressing FRα, destroying them.
The medication is administered via intravenous infusion, usually as part of a specific regimen. It is effective in reducing tumor size and prolonging patient survival.
Side effects may include nausea, fatigue, peripheral neuropathy, and infusion-related reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mirvetuximab soravtansine. This medication must be administered under the supervision of an oncology specialist.
The medication is administered via intravenous infusion, usually as part of a specific regimen. It is effective in reducing tumor size and prolonging patient survival.
Side effects may include nausea, fatigue, peripheral neuropathy, and infusion-related reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mirvetuximab soravtansine. This medication must be administered under the supervision of an oncology specialist.